Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka Holdings Logs Double-Digit Sales, Profit Rise on Abilify in April-September
November 14, 2014
- Combined Half-Year Sales of Major Japanese Drug Makers Up 2.8% Thanks to Overseas Sales
November 14, 2014
- Gene Techno Science Forms Capital Tie-Up with ORTHOREBIRTH to Codevelop, Market Synthetic Bone
November 14, 2014
- Mediceo Initiates Full-Scale Contract PMS Business to Collect Data from GPs
November 14, 2014
- MTPC Files Radicut for Amyotrophic Lateral Sclerosis
November 14, 2014
- Santen Partners with Singapore Eye Research Institute for Development of New Ophthalmic Drugs
November 14, 2014
- CSO Apo Plus Eyes 700 Contract Sales Reps by March 2016
November 14, 2014
- Nihon Chouzai Eyes Scaling Up Production Capacity
November 13, 2014
- Japan Pharma Market Levels Off in July-September: IMS
November 13, 2014
- 90 Pharma Companies Join Forces to Reduce CO2 Emissions; Aiming at 23% Reduction by FY2020
November 13, 2014
- CMIC Holdings, UDG Healthcare Collaborate in CSO, CMO Businesses
November 13, 2014
- Avigan Could Clinch Overseas Approval for Ebola Early Next Year: Fujifilm Official
November 13, 2014
- Fujifilm Sees Healthcare as Growth Engine in Next 3 Years, yet No New Drug Debut until FY2018
November 12, 2014
- Generic Makers Back on Growth Track in First Half of FY2014
November 12, 2014
- Shionogi Lodges Complaint against Tax Reassessment over ViiV Deal
November 12, 2014
- Daiichi Sankyo Completes Tender Offer to Acquire Ambit Biosciences
November 12, 2014
- Takeda, GE Healthcare Forge Alliance for Hepatic Diseases
November 12, 2014
- Ethical Drug Sales Down 0.2% in September Owing to Long-Listed Drug Sales Decline: Crecon Report
November 12, 2014
- BIKEN Begins Clinical Trial of Varicella Vaccine for Herpes Zoster
November 12, 2014
- Dermatology Firm Maruho Eyes US Product Rollout in Next 3 Years
November 12, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…